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Background: Although GATA1 is one of the most extensively studied haematopoietic transcription factors little
is currently known about the physiological functions of its naturally occurring isoforms GATA1s and GATA1FL
in humans—particularly whether the isoforms have distinct roles in different lineages and whether they have
non-redundant roles in haematopoietic differentiation. As well as being of general interest to understanding
of haematopoiesis, GATA1 isoform biology is important for children with Down syndrome associated acute
megakaryoblastic leukaemia (DS-AMKL) where GATA1FL mutations are an essential driver for disease pathogenesis.
Methods: Human primary cells and cell lines were analyzed using GATA1 isoform specific PCR. K562 cells
expressing GATA1s or GATA1FL transgenes were used to model the effects of the two isoforms on in vitro
haematopoietic differentiation.
Results: We found no evidence for lineage specific use of GATA1 isoforms; however GATA1s transcripts, but
not GATA1FL transcripts, are down-regulated during in vitro induction of terminal megakaryocytic and erythroid
differentiation in the cell line K562. In addition, transgenic K562-GATA1s and K562-GATA1FL cells have distinct
gene expression profiles both in steady state and during terminal erythroid differentiation, with GATA1s expression
characterised by lack of repression of MYB, CCND2 and SKI.
Conclusions: These findings support the theory that the GATA1s isoform plays a role in the maintenance of
proliferative multipotent megakaryocyte-erythroid precursor cells and must be down-regulated prior to terminal
differentiation. In addition our data suggest that SKI may be a potential therapeutic target for the treatment of
children with DS-AMKL.
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GATA binding protein 1 (GATA1, GenBank ID:
NM_002049) is a key haematopoietic transcription
factor with a pivotal role in differentiation of the
erythroid, megakaryocyte, eosinophil and mast cell line-
ages[1]. The GATA1 gene produces at least two protein
isoforms—the well characterised GATA1 full-length
(GATA1FL) isoform and a truncated isoform—GATA1
short (GATA1s). The GATA1FL protein comprises
two zinc fingers (which interact with DNA and essential
co-factors) a C-terminal tail (of mostly unknown func-
tion) and an N-terminal domain (originally thought
to confer activation properties to the molecule, but
which may also be involved in transcriptional repression
[2]). GATA1s lacks the N-terminal domain but is other-
wise identical.
The biological role of GATA1s in humans is unknown
and this isoform received scant attention until the dis-
covery that GATA1FL mutations were linked to a highly
informative pair of disorders—transient abnormal
myelopoiesis (TAM)[3] and acute megakaryoblastic leu-
kaemia (AMKL)[4,5]—seen in children with Down syn-
drome (constitutional trisomy 21, OMIM ID: 190685).
In these disorders the GATA1FL mutations are always
clustered within the N-terminus, allowing unhindered
production of the GATA1s isoform. This finding has led
to interest in the pathological and physiological role of
GATA1s in haematopoiesis.
The biological effects of GATA1s have been studied
using transgenic mice and in vitro rescue of GATA1
deficient cells [6–9]. These papers show that GATA1s
expression, in the absence of GATA1FL, is associated
with defects in lineage restriction, alternative cell fate
decisions and proliferation/cell cycle control. In particu-
lar unopposed GATA1s expression is associated with
outgrowth of primitive hyper-proliferative megakaryo-
cytic progenitors with a limited capacity to undergo
terminal differentiation [6–8]. However, concerns remain
about translating results from murine systems into
humans since mouse models do not recapitulate all the
features of human disease [7,10,11]. In addition, whilst
mice produce the two isoforms via alternative translation
of a single GATA1 mRNA [12], humans use alternative
splicing of a pre-mRNA to produce both GATA1FL and
GATA1s transcript [13]. Alternative splicing provides a
mechanism by which the isoforms could be individually
regulated, raising the possibility that alternative isoform
usage occurs in particular lineages or at specific stages
of haematopoietic differentiation. For these reasons
we chose to address three questions regarding the role
of GATA1 isoforms in human haematopoiesis; 1) Do dif-
ferent lineages show different isoform usage? 2) Are
isoform expression levels dynamically regulated during
haematopoietic differentiation? 3) Do the two isoformshave different effects on the transcription of key target
genes during in vitro differentiation?
Results and discussion
GATA1 isoforms are not separately expressed in different
cell types
Both isoforms are known to be expressed in human
CD34+ cells [14] and erythroblasts and megakaryocytes
[10]. Here we extend these observations by using RT-PCR
to detect isoform expression in other human primary cells
(Figure 1a). Eosinophils expressed both isoforms whilst, as
expected, the lymphoid B and T cells did not express ei-
ther isoform. We also studied monocytes and dendritic
cells since the role of GATA1 in dendritic cell (DC) matur-
ation is currently debated [15–17]. Human CD14+ cell
preparations only weakly expressed both isoforms but
maturation into DCs was associated with loss of expres-
sion of both transcripts both by RT-PCR (Figure 1a) and
quantitative PCR (data not shown), arguing against a
major role for GATA1 isoforms in DC development.
To overcome concerns about possible contamination
of primary preparations with other cell types, a number
of cell lines were also studied (Figure 1b). An acute
monocytic leukaemia cell line THP-1 and the histiocytic
(monocyte/macrophage) cell line U937, did not express
either isoform. Expression of both isoforms was seen in
the megakaryocytic cell lines Meg-01 and MO7-E along
with K562 (a chronic myeloid leukaemia cell line known
to be capable of both megakaryocytic and erythroid dif-
ferentiation in vitro). In addition the mast cell lines
HMC-1 and LAD2 expressed both isoforms although,
interestingly, they appeared to have a relatively weak
GATA1s band compared to other cell types.
Importantly, in all the cells we examined the two isoforms
appear to always be expressed together with no evidence
of exclusive GATA1s or exclusive GATA1FL expression in
any of the cell types. This observation argues against a
primary role for the two isoforms in lineage specification.
GATA1 isoform expression is dynamically regulated
during induction of haematopoietic differentiation
It is known that total GATA1 levels show initial up-
regulation during erythroid commitment followed by ter-
minal down-regulation [1,18]. Whether the two GATA1
isoforms are independently regulated at the transcrip-
tional level during this process is unknown. To investi-
gate this, we used an established in vitro model of
Haemin-induced erythroid differentiation in K562 cells
[19]. Successful differentiation was confirmed by a visible
haemoglobinised cell pellet as well as up-regulation of
glycophorin A (Figure 2a). Quantitative PCR using GATA1
isoform specific primers and probes was performed at
baseline and then 6 h, day 3 and day 6 following treatment
(Figure 2b, c).
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Figure 1 Expression patterns of GATA1FL and GATA1s in haematopoietic cells. (a) RT-PCR of human primary cell cDNA using GATA1 exon 1
and 3 primers (top panel) and GAPDH housekeeping gene primers (Bottom panel). Predicted size of GATA1FL= 430 bp and GATA1s= 192 bp (b)
RT-PCR of human haematopoietic cell line cDNA using the same primers as (a).
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Figure 2 GATA1s expression levels during haematopoietic differentiation of K562 cell lines by Haemin and TPA. (a) K562 surface
glycophorin A expression measured by single colour FACS after 3 days of Haemin treatment (MFI =−Mean Fluorescence Intensity) (b, c)
quantitative PCR analysis of (b) GATA1FL and (c) GATA1s, expression levels during the course of Haemin-induced erythroid differentiation (n = 3),
results are expressed as fold change (log2) using day 0 as the calibrator (expression arbitrarily set at 1.0) (d) DNA ploidy analysis in K562 cells 0, 1,
2 and 3 days following treatment with the differentiating agent TPA (e, f) quantitative PCR analysis of (e) GATA1FL and (f) GATA1s, expression
levels during the course of TPA-induced megakaryocytic differentiation (n = 3), results are expressed as fold change (log2) using day 0 as the
calibrator (expression arbitrarily set at 1.0).
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ring differentiation but GATA1s showed a significant up-
regulation at 6 h and down regulation by day 3 compared
to baseline expression levels.
We went on to see whether similar dynamic changes
are seen during in vitro megakaryocytic differentiation
of K562 using TPA [20]. Successful differentiation was
confirmed by an increase in DNA ploidy (Figure 2d)
and by induction of expression of the megakaryocytic
genes ITGA2B and GPB1A (data not shown). Analysis of
GATA1 isoform expression levels (Figure 2e, f ) showed
an initial reduction in both isoforms at 6 h. Again,
GATA1s transcripts remained suppressed at later time-
points whilst GATA1FL transcripts rose to above baseline.
Although the effects are modest, the fact that levels of
the two isoforms can move in opposite directions sug-
gests that their expression can be independently and
dynamically regulated. Our observation of GATA1s down-
regulation from day 3 onwards fits into the prevailing
model of GATA1s function which suggests that GATA1s
is important for maintenance of a suitable primed highly
proliferative progenitor compartment but that a switch to
predominant GATA1FL usage may be needed to enact
terminal differentiation.
GATA1FL and GATA1s transfectants show distinct
transcriptional profiles during haemin induced in vitro
differentiation
To extend these observations further we looked at the
impact of isoform expression on transcriptional profiles
during erythroid differentiation. K562 cells were stably
transfected with a GATA1s-IRESGFP or GATA1FL-
IRESGFP expressing plasmid or an empty vector control
and high GFP expressers were sorted and used in all
subsequent experiments. Details of the construction and
validation of these vectors are given in the materials and
methods section and outlined in Figure 3. The presence
of empty vector had no effect on growth characteristics
compared to the parental cell line (p = 0.6, 2-way
ANOVA untransfected K562 vs. empty vector). Both
GATA1FL and GATA1s transfection conferred a modest
but significant growth advantage to the K562 cells
(GATA1FL vs. empty vector p = 0.03, GATA1s vs. empty
vector p = 0.02, student’s 2 tailed t-test), but there
was no difference between the two isoforms (p = 0.40
GATA1FL vs. GATA1s). Since the lower proliferation in
the empty vector transfectants could confound compari-
son of transcriptional profiles it was decided to directly
compare GATA1FL vs. GATA1s transfectants in subse-
quent analysis. Although this cannot completely rule out
off-target effects related to the presence of the vector
the two transfectants should be equally affected by
this. We used this system to answer the question of
whether the GATA1s and GATA1FL isoforms producedifferential effects on transcription when over-expressed
in the same cellular context. All experiments were per-
formed in triplicate.
Using data from microarray studies in Down syndrome
AMKL [21,22] and GATA1 transgenic mice [7] we iden-
tified eight potentially informative genes and examined
their response to in vitro erythroid differentiation in our
engineered cell lines. Results of gene expression levels
were compared between the GATA1FL and GATA1s
transfectants at day 0 (baseline), day 1 and day 3 of dif-
ferentiation using ΔΔCT relative quantification (n = 3,
Figure 4). GATA1FL expressing cells formed a well hae-
moglobinised cell pellet by day 1 of differentiation
whereas GATA1s cells formed a haemoglobinsed pellet
by day 3 indicating a potential slowing but no absolute
block to differentiation.
Two genes—Ikaros and NFE2—were down regulated
in GATA1FL transfectants but to a lesser extent in
GATA1s transfectants. Inadequate repression of Ikaros
(a master regulator of lymphoid differentiation [23]) has
already been described in the GATA1s transgenic mice
[7] and is thought to be consistent with maintenance
of a primed multipotent progenitor state. The reduced
repression of NFE2, an important megakaryocytic tran-
scription factor [24], may partially explain the strong
association of GATA1s with acute megakaryoblastic leu-
kaemia [4].
A second set of genes—EKLF, PU.1 and GATA2 show
some alterations at baseline but no significant differ-
ences in response to differentiation. In the GATA1s
transgenic mouse model [7] PU.1 and GATA2 showed
inadequate repression during in vitro megakaryocytic
differentiation. The different result seen here may be
due to differences between erythroid and megakaryo-
cytic differentiation regimes, expression of a dominant
GATA1FL isoform from the endogenous K562 allele or
it may reflect differences in the transcriptional response
to GATA1s between mice and humans.
Perhaps the most interesting genes were those that
showed persistent up-regulation in the presence of GATA1s;
MYB, CCND2 and SKI. MYB is a key haematopoietic
transcription factor involved in stem cell self-renewal
and lineage decisions [25]. In the GATA1s transfectants
MYB persisted at higher levels than undifferentiated
GATA1FL cells consistent with maintenance of a primi-
tive progenitor state. Interestingly one of the key findings
from GATA1s transgenic mice is that fetal liver derived
megakaryocytic precursors failed to down-regulate MYB
when differentiated in vitro [7]. These results confirm
these findings in a completely different (and human)
experimental system. Our second gene of interest was
CCND2, a cell cycle regulator. Since CCND2 is asso-
ciated with megakaryocytic differentiation [26] down-
regulation would be expected during terminal erythroid
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Figure 3 Production and validation of GATA1 isoform specific expression vectors. (a) production of GATA1s and GATA1FL transcripts from
wild type (WT) HEK293 cDNA black arrows represent the position of the GATA1WT/FL primers, white arrows mark GATA1s primers. (b) Map of the
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tants but not GATA1s consistent with its proposed
role in bipotent meg-erythroid and megakaryocytic cells.
Finally SKI is known to show peak expression in murine
bipotent meg-erythroid progenitors (MEP) with much
lower or undetectable levels in earlier precursors or uni-
potent megakaryocytic or erythroid precursors [27]. It
has been shown to block erythroid differentiation by a
direct interaction with GATA1 involving the C-terminal
Zinc finger [28]. SKI is an important component of the
histone deacetylase complex, and over-expression of SKI
has been implicated in the pathogenesis of acute myeloid
leukaemia [29–31]. These observations suggest that aGATA1s-SKI interaction may be important for the main-
tenance of an expanded MEP compartment with a block
to terminal differentiation as seen in transient abnormal
myelopoiesis. The precise role of SKI in Down syndrome
transient abnormal myelopoiesis needs further investiga-
tion particularly as this raises the possibility that these
children may respond well to relatively non-toxic HDAC
inhibitors currently in development [32].
Conclusions
The data presented here show that the two GATA-1 iso-
forms can be independently regulated at the transcrip-
tional level during haematopoietic differentiation but we
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specify different lineages. When overexpressed during
human erythroid differentiation the two isoforms produce
distinct transcriptional profiles which largely mirror those
seen in murine models. Finally our observation of sus-
tained SKI up-regulation by GATA1s suggests a potential
target gene which may play an important role in the deve-
lopment of DS-AMKL and is a tractable therapeutic target.
Methods
Cell lines
THP-1, U937, K562, and Meg01 cell lines were grown
in complete RPMI 1640 with 10% fetal bovine serum
(FBS). MO7E were grown in RPMI supplemented with
20% FBS and 10 ng/ml GM-CSF (StemCell Techno-
logies). HMC-1 cells were grown in IMDM supplemen-
ted with 10% FBS, 25 mM HEPES, and α-thioglycerol.
LAD2 cells were grown in Stem pro-34 SFM media sup-
plemented with stem pro-34 nutrient supplement (Invi-
trogen) plus 10 ng/ml human Stem Cell Factor
(StemCell Technologies).
Primary cells
Human peripheral blood (PB) eosinophils, T and B cell
populations were isolated from human PB as previouslydescribed [16]. Cell purities were verified by staining for
CD4 (T cells >95%) and CD19 (B cells >95%). Monocytes
were isolated using human buffy coats layered over
Ficoll-Paque (GE Healthcare). The mononuclear cell
fraction was washed and CD14+ cells separated using
microbeads and an autoMACS Pro separator, following
the manufacturer’s protocol (Miltenyi Biotec). Cell
purities were consistently >90% by flow cytometry. To
generate immature dendritic cells (DCs) (CD14-HLA-
DRmidCD86mid) the CD14+ cells were grown for 6 days
in RPMI 1640, supplemented with HEPES, L-glut
(Invitrogen), 5% AB serum, gentamicin (Sigma), 50 ng/mL
GM-CSF and 15 ng/mL IL-4 (Miltenyi Biotec). Immuno-
phenotype was confirmed by flow cytometry (MACSQuant,
Miltenyi Biotec). Mature DCs (CD14-HLA-DRhighCD83+
CD86+CD80+CD25+) were generated by resuspension
of the immature DC fraction in RPMI 1640 supplemen-
ted with 5% AB serum, gentamicin, HEPES, L-glut,
50 ng/mL GM-CSF, 15 ng/mL IL-4, 12.5 μg/mL PolyI:C
(Sigma) and 1 μg/mL PGE2 (Sigma) for 48 h. Again iden-
tity was confirmed by flow cytometry.
Expression plasmids
GATA1FL and GATA1s isoforms were amplified from
a GATA1-BFT4 expression plasmid using exon 2
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mers respectively along with a common exon 6 reverse
primer (gctattctgtgtaccttcaagaac) (Figure 3a) and cloned
into pcDNA3.1 expression plasmids (Invitrogen). The
GATA1FL plasmid then underwent site directed mutage-
nesis (QuikChangeII, Stratagene) of the second start codon
at position 84 (ATG to ACA), to prevent alternative trans-
lation of GATA1s from the same transcript (Figure 3a).
Products were subcloned into the pEF6V5hisTOPO ex-
pression vector (Invitrogen) and an IRES GFP sequence
was ligated into a downstream NotI site to produce the
vectors GATA1s-IRESGFP, GATA1FL-IRESGFP and an
Empty vector control containing all vector sequences but
no GATA1 insert: Empty-IRESGFP (Figure 3b). Protein ex-
pression from the GATA1s and GATA1FL vectors was
confirmed by western blotting of transfected HEK293 cells
(GATA1 M20 antibody, Santa Cruz) (Figure 3c). Transac-
tivation of a GATA1 luciferase reporter vector was used to
confirm that the amino-acid 84 (Met-Thr) change, intro-
duced by site directed mutagenesis, did not produce a
functional change in the GATA1FL protein (Figure 3d).
The vectors were stably transfected into K562 cells
using Fugene6 (Promega) and maintained in selective
Blasticidin containing media. Following several weeks in
culture high GFP expressors were isolated using a BD
FACSAria cell sorter before use in in vitro differentiation
experiments.
Haemin and TPA differentiation
Differentiation of K562 cells was achieved by plating
1 × 106 cells in each well of a 6-well plate and treating
for up to 4 days with 100 nM 12-O-tetradecanoyl phor-
bol-13-acetate (TPA) [33] or 10 μM Haemin (from a
4 mM stock dissolved in NaOH 0.5 M, Tris (pH 7.8))
[19]. All experiments were preformed in triplicate.
Flow cytometry
Cells were washed and treated with human Fc receptor
Blocking agent (Miltenyi Biotec) followed by mouse anti-
human PE-Cy5 conjugated anti-CD235a (glycophorin A)
(BD Pharmingen). Data was acquired from 20,000 gated
events on a FACSCalibur instrument (Becton Dickinson)
and analyzed using BD CellQuest Pro software.
DNA ploidy analysis
Cells were washed in cold PBS and added drop-wise to
ice-cold ethanol. Following overnight incubation at 4°C
cells were spun down and resuspended in 2 ml of Propi-
dium Iodide (PI) mastermix (1xPBS, PI 40 μg/ml, RNase
(DNAse-free) 100 μg/ml) and incubated at 37°C for
30 min. Cells were filtered through a 40–70 μm cell
strainer and analysed on the flow cytometer as detailed
above. A known 2N cell line (Raji) was used as a control
and run alongside test samples.RT and qPCR
Total RNA was extracted from cell lysates using RNeasy
columns (Qiagen) with on-column DNase digestion
(RNase-free DNase, Qiagen). RNA (2 μg) was reverse-
transcribed using random primers and AffinityScript
multiple temperature Reverse Transcriptase (Stratagene).
The resulting cDNA was diluted 1:5 and standard RT-
PCR was performed using a commercial PCR mastermix
(ReddyMix, Abgene) with the following primers: GATA1
5′ ctccgcaaccaccagcccag 3′ tatggtgagccccctgggatc. The iden-
tity of PCR products was confirmed by excision of bands
from the agarose gel, purification of DNA using a commer-
cial QIAquick gel extraction method (Qiagen), followed by
TOPO cloning into a pCR4TOPO vector (Invitrogen). Plas-
mid preparations containing insert were then sent for com-
mercial sequencing (www.agowa.de).
Quantitative PCR (qPCR) was performed on a 7900HT
(Applied Biosystems (ABI)) thermal cycler using Taqman
technology (ABI). Previously published GATA1 isoform
primers and probes were used [14]. GATA1 transcript
levels were normalized to 18s rRNA (one of several refe-
rence genes analyzed and found to be unaffected by ex-
perimental conditions). Gene expression signatures were
analyzed on 384 well microfluidic plates (Taqman low
density array (TLDAWplates), ABI) using Universal PCR
Mastermix (ABI). Results were analyzed using Sequence
Detection Systems (SDS) Software v2.1 and statistical ana-
lysis was performed using a two-tailed student’s t-test with
a p value of ≤0.05 being considered significant.
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